Gynaecologic Effects of Tamoxifen

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 1995 Jun 1

PMID 8535666

Citations 1

Authors

D Y Kuo

C D Runowicz

Affiliations

Soon will be listed here.

Abstract

Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.

Citing Articles

Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms.

Watters J, Dorsa D J Neurosci. 1998; 18(17):6672-80.

PMID: 9712639 PMC: 6792960.

References

Ford M, Turner M, Wood C, Soutter W . Endometriosis developing during tamoxifen therapy. Am J Obstet Gynecol. 1988; 158(5):1119. DOI: 10.1016/0002-9378(88)90233-5. View

Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer M . Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report. Gynecol Oncol. 1991; 42(2):120-3. DOI: 10.1016/0090-8258(91)90330-8. View

Jolles C, Smotkin D, Ford K, Jones K . Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report. J Reprod Med. 1990; 35(3):299-300. View

Cohen I, Tepper R, Rosen D, Shapira J, Cordoba M, Dror Y . Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol. 1994; 55(1):138-43. DOI: 10.1006/gyno.1994.1263. View

Cohen I, Rosen D, Tepper R, Cordoba M, Shapira Y, Altaras M . Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993; 12(5):275-80. DOI: 10.7863/jum.1993.12.5.275. View

Miodrag A, Ekelund P, Burton R, Castleden C . Tamoxifen and partial oestrogen agonism in postmenopausal women. Age Ageing. 1991; 20(1):52-4. DOI: 10.1093/ageing/20.1.52. View

Andersson M, Storm H, Mouridsen H . Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991; 83(14):1013-7. DOI: 10.1093/jnci/83.14.1013. View

Hardell L . Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet. 1988; 2(8610):563. DOI: 10.1016/s0140-6736(88)92675-x. View

Manni A, Pearson O . Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep. 1980; 64(6-7):779-85. View

10.

Cross S, Ismail S . Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report. Br J Obstet Gynaecol. 1990; 97(2):190-2. DOI: 10.1111/j.1471-0528.1990.tb01748.x. View

11.

Murphy L, Gong Y, Murphy L . Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol. 1992; 41(3-8):309-14. DOI: 10.1016/0960-0760(92)90356-n. View

12.

Magriples U, Naftolin F, Schwartz P, Carcangiu M . High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993; 11(3):485-90. DOI: 10.1200/JCO.1993.11.3.485. View

13.

Altaras M, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y . Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas. Gynecol Oncol. 1993; 49(2):255-8. DOI: 10.1006/gyno.1993.1118. View

14.

Love R, Newcomb P, Wiebe D, Surawicz T, Jordan V, Carbone P . Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990; 82(16):1327-32. DOI: 10.1093/jnci/82.16.1327. View

15.

McDonald C, Stewart H . Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991; 303(6800):435-7. PMC: 1670561. DOI: 10.1136/bmj.303.6800.435. View

16.

Mortel R, Levy C, WOLFF J, Nicolas J, Robel P, Baulieu E . Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen. Cancer Res. 1981; 41(3):1140-7. View

17.

de Muylder X, Neven P, De Somer M, van Belle Y, Vanderick G, DE MUYLDER E . Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet. 1991; 36(2):127-30. DOI: 10.1016/0020-7292(91)90767-y. View

18.

Whittemore A . Fertility drugs and risk of ovarian cancer. Hum Reprod. 1993; 8(7):999-1000. DOI: 10.1093/oxfordjournals.humrep.a138217. View

19.

. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992; 339(8784):1-15. View

20.

van Leeuwen F, Benraadt J, Coebergh J, Kiemeney L, Gimbrere C, Otter R . Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994; 343(8895):448-52. DOI: 10.1016/s0140-6736(94)92692-1. View